Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Current Opinion in Supportive and Palliative Care|July 7, 2018
Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancerPasquale Rescigno, Robert Chandler, Johann de Bono
BMC Cancer|January 27, 2022
Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trialsMichael J Grayling, Martina McMenamin, Robert Chandler, et al.
Molecular and Cellular Neurosciences|June 12, 2002
The axonal localization of large Drosophila ankyrin2 protein isoforms is essential for neuronal functionalityMichael Hortsch, Kerry L Paisley, Ming-Zhu Tian, et al.
Clinical Endocrinology|April 6, 2020
Differentiated thyroid cancer mortality by disease stage in northern EnglandPetros Perros, David Mason, Mark Pearce, et al.
Pediatric Radiology|January 7, 2005
Imaging of acute appendicitis: US as the primary imaging modalityJ Alberto Hernandez, Leonard E Swischuk, Carlos A Angel, et al.
Chinese Clinical Oncology|September 2, 2025
New hormonal agents and integrated strategies for non-metastatic, hormone-sensitive prostate carcinoma: the orphan setting?-a narrative reviewFabrizio Di Costanzo, Iolanda Santa Parisi, Giuseppe Neola, et al.
NIHR Open Research|October 25, 2023
Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trialPaul Gravestock, Emma Clark, Miranda Morton, et al.
European Urology|October 21, 2018
Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair DeficiencyZafeiris Zafeiriou, Diletta Bianchini, Robert Chandler, et al.
The Lancet. Oncology|December 7, 2019
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquin Mateo, Nuria Porta, Diletta Bianchini, et al.
Pageof 1